Rapt Therapeutics (NASDAQ:RAPT) Given Average Rating of "Hold" by Analysts

Shares of Rapt Therapeutics (NASDAQ:RAPT - Get Free Report) have earned a consensus rating of "Hold" from the six research firms that are currently covering the stock, Marketbeat reports. One analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation, one has assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month price target among analysts that have issued ratings on the stock in the last year is $24.00.

RAPT has been the topic of several recent analyst reports. UBS Group cut their price target on shares of Rapt Therapeutics from $16.00 to $8.00 and set a "neutral" rating on the stock in a report on Thursday, May 22nd. Wall Street Zen lowered shares of Rapt Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday, June 21st. Finally, HC Wainwright upgraded shares of Rapt Therapeutics to a "strong-buy" rating and set a $48.00 price target on the stock in a research report on Thursday, May 22nd.

Institutional Trading of Rapt Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the business. Simplicity Wealth LLC purchased a new position in Rapt Therapeutics during the 1st quarter valued at about $25,000. Picton Mahoney Asset Management lifted its holdings in shares of Rapt Therapeutics by 994.4% during the fourth quarter. Picton Mahoney Asset Management now owns 16,175 shares of the company's stock valued at $26,000 after purchasing an additional 14,697 shares during the last quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC purchased a new position in shares of Rapt Therapeutics during the fourth quarter valued at approximately $63,000. Sei Investments Co. bought a new stake in shares of Rapt Therapeutics in the 4th quarter worth approximately $64,000. Finally, Invesco Ltd. grew its stake in shares of Rapt Therapeutics by 411.7% in the 1st quarter. Invesco Ltd. now owns 58,901 shares of the company's stock worth $72,000 after buying an additional 47,391 shares during the last quarter. 99.09% of the stock is owned by hedge funds and other institutional investors.

Rapt Therapeutics Price Performance

NASDAQ RAPT opened at $8.43 on Friday. Rapt Therapeutics has a 1 year low of $5.67 and a 1 year high of $30.60. The stock has a market capitalization of $139.43 million, a PE ratio of -0.44 and a beta of -0.11. The business's 50-day moving average is $7.66 and its 200 day moving average is $8.89.

Rapt Therapeutics (NASDAQ:RAPT - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The company reported ($0.64) earnings per share for the quarter, topping analysts' consensus estimates of ($2.48) by $1.84. As a group, equities research analysts anticipate that Rapt Therapeutics will post -2.14 earnings per share for the current year.

About Rapt Therapeutics

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.